Login / Signup

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors.

Seokuee KimSujong KimYoung Suk ParkJoon Oh ParkHo Yeong LimJin Seok AhnJeeyun LeeJong Mu SunWon Ki KangRaeO HanJung-Ryul KimMyung-Ju Ahn
Published in: Expert opinion on investigational drugs (2020)
Doses equal to or greater than 10 mg/day KML001 alone were tolerable and produced plasma concentrations higher than biologically relevant targets.
Keyphrases
  • clinical trial
  • open label
  • phase ii
  • combination therapy
  • study protocol
  • double blind
  • phase iii
  • randomized controlled trial